IBI318 + paclitaxel

IBI318 + paclitaxel is a combination regimen consisting of **IBI318 (LY3434172)**, a fully human bispecific monoclonal antibody that targets both **Programmed cell death protein 1 (PD-1)** and **Programmed cell death ligand 1 (PD-L1)**, and **paclitaxel**, a well-established cytotoxic chemotherapeutic agent. IBI318 is engineered to block the interaction between PD-1/PD-L1 and PD-L2/CD80, resulting in enhanced activation of effector T cells and increased tumor cell death. Paclitaxel disrupts microtubule function, leading to cell cycle arrest and tumor cell apoptosis. The combination is being evaluated for its safety and efficacy in patients with advanced cancers, including small cell lung cancer, who have failed first-line or subsequent chemotherapies[1][3][5].

Other names

IBI318 + paclitaxel